by European Public Health Alliance | Jun 21, 2021 | #VaccineEquity, COVID-19, Health Inequalities
The European Public Health Alliance has called on the European Centre for Disease Prevention and Control (ECDC) to take action in the monitoring of monitoring of the vaccine distribution within EU Member States, following concerns regarding the risk of delay and...
by European Public Health Alliance | May 3, 2021 | COVID-19, Health Workforce
Guest article: Corinne Hinlopen, Global Health Advocate and Policy Researcher at Wemos FoundationIn spite of ambitions to emerge stronger from the COVID-19 crisis, Europe’s €672.5 billion COVID Recovery Package is intended for national recovery plans only. But in an...
by European Public Health Alliance | Apr 27, 2021 | #EU4Health, COVID-19
Learning lessons from the COVID-19 pandemic, EPHA joins a range of health organisations (representing patients, healthcare professionals and medical societies, industry, public institutes and broader health advocacy groups) to call on the EU Council to extend the...
by European Public Health Alliance | Feb 10, 2021 | COVID-19, Non Communicable Diseases (NCDs), Universal Access and Affordable Medicines | Latest Developments
EPHA has joined a number of organisations led by EPHA member the Anticancer Fund calling for the repurposing of various drugs already widely used for non-cancer diseases which have shown promise for the treatment of cancer, allowing new cancer treatments to be...
by European Public Health Alliance | Feb 3, 2021 | #VaccineEquity, COVID-19, Roma Health | Analysis and Opinion
Guest article by: Maja Saitovic, Program Officer, Race, Ethnicity and Health Equity team, Open Society Foundations’ Public Health Program; Marek Szilvasi, PhD., Team Manager, Race, Ethnicity and Health Equity team, Open Society Foundations’ Public Health ProgramThe...
by Yannis Natsis | Dec 17, 2020 | COVID-19, Universal Access and Affordable Medicines | Latest Developments
39 civil society organisations including EPHA are calling on the European Commission and EU national governments to ensure a maximum degree of transparency in the EU’s exchanges, negotiations and deals with pharmaceutical companies over COVID19 vaccines, proposing a...
